|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
This retrospective analysis evaluated the incidence, risk factors, and types of infectious complications (IC) in adults with CD20+ non-Hodgkin lymphoma who received ≥2 cycles of B and either R or ofatumumab.
|
31603363 |
2020 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
HBV DNA monitoring-guided preemptive NAT was effective in preventing HBV-related hepatitis during anti-CD20-containing immunochemotherapy in B-cell NHL patients with resolved HBV infection.
|
30341058 |
2019 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence indicates that the anti-CD20 monoclonal antibody rituximab significantly improves the clinical prognosis of patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.
|
30655772 |
2019 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-CD47 drug Hu5F9-G4, also known as 5F9, in combination with the anti-CD20 therapy rituximab, may be a promising treatment for some forms of non-Hodgkin lymphoma because it allows macrophages to recognize and attack cancer cells.
|
30464001 |
2019 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
|
31772298 |
2019 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, we developed a rituximab (anti-CD20)-modified mTOR inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) for trial of its anti-NHL effect.
|
30198340 |
2018 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that NK-92MIhCD16 and NK-92MIhCD64 cells significantly improved cytotoxicity against CD20-positive non-Hodgkin's lymphoma cells in the presence of rituximab.
|
28415754 |
2017 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab was administrated at 375 mg/m<sup>2</sup> on day 1 for CD20+ NHL.
|
28374163 |
2017 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma.
|
29054987 |
2017 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Facilitating the development of alternative targeted therapeutic strategies is urgently required to improve outcome or circumvent chemotherapy resistance in children, adolescents, and adults with recurrent/refractory de novo mature B-cell (CD20) non-Hodgkin lymphoma, including Burkitt lymphoma (BL).
|
28932644 |
2017 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unvaccinated HBsAg-seronegative adults (n = 104) with CD20 NHL who had received rituximab-containing therapy without anti-HBV prophylaxis were enrolled.
|
26986131 |
2016 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab (RTX), a chimeric mouse anti-human CD20 monoclonal antibody, is indicated for the treatment of patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis, and rheumatoid arthritis, but nowadays it is increasingly used for the treatment of many other immune-mediated disorders.
|
24909454 |
2014 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.
|
23121392 |
2013 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Studies in non-Hodgkin lymphoma demonstrated a relationship between the FcGRIIIa polymorphism and response to anti-CD20 therapies.
|
23294992 |
2013 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consequently, B10 cell removal could provide a way to optimize CD20 mAb-mediated clearance of malignant B cells in patients with non-Hodgkin lymphoma.
|
22019587 |
2011 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notable examples include trastuzumab, a humanized monoclonal antibody (mAb) against human epidermal growth factor receptor (HER)-2 in women with HER2-positive breast cancer; rituximab, an anti-CD20 mAb in patients with non-Hodgkin's lymphoma; imatinib, a tyrosine kinase inhibitor in KIT-positive gastrointestinal stromal tumours and sunitinib, another tyrosine kinase inhibitor, in metastatic renal cell carcinoma.
|
21300696 |
2011 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
So adoptively T cells transduced anti-CD20scFvFc/CD28/CD3zeta gene mediates enhanced anti-tumor activities against CD20 positive tumor cells, suggesting a potential of gene-based immunotherapy for non-Hodgkin lymphoma.
|
20815894 |
2010 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin (IL)-21, a member of the IL-2 family, has antitumor activity and is now being tested in non-Hodgkin's lymphoma in combination with anti-CD20 antibodies.
|
20193734 |
2010 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Incorporation of the chimeric CD20 monoclonal antibody rituximab in the treatment schedule of patients with non-Hodgkin's lymphoma has significantly improved outcome.
|
20851867 |
2010 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to analyze expression of complement inhibitors CD46, CD55, and CD59 in patients with CD20(+) NHLs treated with rituximab combined with chemotherapy.
|
19662541 |
2010 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin lymphoma as well as autoimmune disorders.
|
20194898 |
2010 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
|
19276251 |
2009 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The resultant fusion protein, designated scFvRit:sFasL, potently induced CD20-restricted apoptosis in a panel of malignant B-cell lines (10 of 11) and primary patient-derived malignant B cells (two of two non-Hodgkin lymphoma and five of six B cell chronic lymphocytic leukemia).
|
18199557 |
2008 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ten patients (age 31-70 years, mean 50 years) were included, nine with CD20 B-cell NHL and one with CD20-NHL.
|
18987526 |
2008 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting malignant B cells using rituximab (anti-CD20) has improved the efficacy of chemotherapy regimens used to treat patients with non-Hodgkin's lymphoma.
|
18316580 |
2008 |